secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001493152-26-005796
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity appoints three lung cancer specialists to Medical and Scientific Advisory Board
--------------------------------------------------------------------------------

- David Ost (MD Anderson), Daniel Sterman (NYU Langone) and J. Scott Ferguson (Univ. of Wisconsin) joined the advisory board.
- Advisory board provides guidance on clinical priorities and broader adoption of CyPath® Lung diagnostic test.
- CyPath® Lung is a noninvasive test for early lung cancer detection with 92% sensitivity and 87% specificity in clinical studies.
- New appointees join current members including David Hill, Neil Alexis, Sheila Habib, and Sandeep Bansal.
- Company says appointments align with its focus on integrating CyPath® Lung into standard care for indeterminate pulmonary nodules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226005796/0001493152-26-005796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226005796/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer